ReviewInfection & chemotherapy2018
Albendazole and Praziquantel: Review and Safety Monitoring in Korea.
Review in Infection & chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 62 citations in OpenAlex.
- Postoperative Prophylaxis of Cystic Echinococcosis with Albendazole and Praziquantel: A Retrospective Cohort Study.Biomedicines · 2026Article
- Assessment of the therapeutic efficacy of Holothuria polii extract during the muscular phase of Trichinella spiralis infection in albino mice.Scientific reports · 2026Article
- Earthworm gut microbiome promotes biodegradation of albendazole in soil.Crop health · 2026Article
- Synergistic interaction between praziquantel and oxfendazole or fenbendazole in a murine cysticercosis model.Antimicrobial agents and chemotherapy · 2025Article
- Hydatid Cyst in Pregnancy-A Diagnostic and Therapeutic Dilemma: Study Case Report.Journal of clinical medicine · 2025Article
- The hidden threat of cysticercosis: A neglected public health problem.Open veterinary journal · 2025Review
- Black seed oil nanoemulsion containing albendazole against protoscoleces ofIranian journal of basic medical sciences · 2025Article
- Evaluation of anthelminthic and antiprotozoal activity of myrrh (Helminthologia · 2024Article
- Paragonimiasis.Advances in experimental medicine and biology · 2024Review
- Anthelmintic efficacy evaluation and mechanism of N-methylbenzo[d]oxazol-2-amine.Scientific reports · 2023Article
- Albendazole Monotherapy for Pediatric Cystic Echinococcosis: A Case Series.Acta parasitologica · 2023Article
- Review
- Evaluation of albendazole efficiency and complications in patients with pulmonary hydatid cyst.Interactive cardiovascular and thoracic surgery · 2022Article
- Article
- Coding and Noncoding RNA Expression Profiles of Spleen CD4Contrast media & molecular imaging · 2022Article
- Pathogens and Carcinogenesis: A Review.Biology · 2021Review
- Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.The Korean journal of parasitology · 2021Review
- Therapeutic efficacy of mebendazole and artemisinin in different phases of trichinellosis: a comparative experimental study.Parasitology · 2021Article
- Target animal safety evaluation of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for cats.Parasite (Paris, France) · 2021Article
- The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs.Immune network · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albendazole (ADZ) and praziquantel (PZQT) have been used as anthelmintics for over 30 years. Worldwide, hundreds of millions tablets are administered to people and livestock every year. ADZ is poorly orally absorbed (<5%), and its uptake is enhanced by high-fat meals, while PZQT is well absorbed (>75%) and uptake is enhanced by carbohydrate-rich meals. Both ADZ and PZQT are safe, but not recommended for children <2 years or for women in the first trimester of pregnancy. Serious adverse events occur following high dose and prolonged administration of these drugs for treatment of echinococcosis or neurocysticercosis, especially in patients with poor liver function. The adverse events may be induced by the drugs, or by the dead worms themselves. The Korea Institute of Drug Safety & Risk Management monitors drug-related adverse events in Korea, and its database included 256 probable or possible ADZ-associated events and 108 PZQT-associated events between 2006 and 2015. Such low incidence rates in Korea are due to the low single dose treatments of ADZ, and the short-term use of PZQT. The number of serious adverse events due to drug interaction induced by ADZ and PZQT were six and two, respectively. We conclude that ADZ and PZQT are generally safe drugs, but they must be used with caution in people with poor liver function or those being comedicated for gastroesophageal reflux disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.